• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Defective regulatory B-cell compartment in patients with immune thrombocytopenia.免疫性血小板减少症患者的调节性 B 细胞缺陷。
Blood. 2012 Oct 18;120(16):3318-25. doi: 10.1182/blood-2012-05-432575. Epub 2012 Aug 2.
2
[Significance of regulatory B cells in nosogenesis of immune thrombocytopenia].[调节性B细胞在免疫性血小板减少症发病机制中的意义]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Apr;22(2):403-6. doi: 10.7534/j.issn.1009-2137.2014.02.025.
3
Increasing numbers of CD19 + CD24CD38 regulatory B cells and pre-germinal center B cells reflect activated autoimmunity and predict future treatment response in patients with untreated immune thrombocytopenia.越来越多的 CD19+CD24-CD38+ 调节性 B 细胞和生发中心前 B 细胞反映了自身免疫的激活,并可预测未经治疗的免疫性血小板减少症患者的未来治疗反应。
Int J Hematol. 2021 Nov;114(5):580-590. doi: 10.1007/s12185-021-03192-w. Epub 2021 Jul 26.
4
Altered B cell balance, but unaffected B cell capacity to limit monocyte activation in anti-neutrophil cytoplasmic antibody-associated vasculitis in remission.在缓解期的抗中性粒细胞胞浆抗体相关性血管炎中,B 细胞平衡改变,但 B 细胞限制单核细胞活化的能力不受影响。
Rheumatology (Oxford). 2014 Sep;53(9):1683-92. doi: 10.1093/rheumatology/keu149. Epub 2014 Apr 10.
5
CD16+ monocytes control T-cell subset development in immune thrombocytopenia.CD16+ 单核细胞控制免疫性血小板减少症中 T 细胞亚群的发育。
Blood. 2012 Oct 18;120(16):3326-35. doi: 10.1182/blood-2012-06-434605. Epub 2012 Aug 20.
6
Reduced CD5(+) CD24(hi) CD38(hi) and interleukin-10(+) regulatory B cells in active anti-neutrophil cytoplasmic autoantibody-associated vasculitis permit increased circulating autoantibodies.活动性抗中性粒细胞胞浆自身抗体相关性血管炎中CD5(+) CD24(高表达) CD38(高表达)和白细胞介素-10(+)调节性B细胞减少,使得循环自身抗体增加。
Clin Exp Immunol. 2015 May;180(2):178-88. doi: 10.1111/cei.12483.
7
Autoimmune thrombocytopenia: flow cytometric determination of platelet-associated CD154/CD40L and CD40 on peripheral blood T and B lymphocytes.自身免疫性血小板减少症:流式细胞术检测外周血T和B淋巴细胞上血小板相关的CD154/CD40L和CD40
Hematology. 2007 Aug;12(4):301-7. doi: 10.1080/10245330701383957.
8
Restoration of regulatory B cell deficiency following alemtuzumab therapy in patients with relapsing multiple sclerosis.在复发型多发性硬化症患者中,阿仑单抗治疗后调节性 B 细胞缺陷的恢复。
J Neuroinflammation. 2018 Oct 30;15(1):300. doi: 10.1186/s12974-018-1334-y.
9
Purification and Immunophenotypic Characterization of Human CD19CD24CD38 and CD19CD24CD27 B Cells.人 CD19CD24CD38 和 CD19CD24CD27 B 细胞的纯化和免疫表型特征。
Methods Mol Biol. 2021;2270:77-90. doi: 10.1007/978-1-0716-1237-8_5.
10
PD-L1 Regulatory B Cells Are Significantly Decreased in Rheumatoid Arthritis Patients and Increase After Successful Treatment.PD-L1 调节性 B 细胞在类风湿关节炎患者中显著减少,并在成功治疗后增加。
Front Immunol. 2018 Oct 1;9:2241. doi: 10.3389/fimmu.2018.02241. eCollection 2018.

引用本文的文献

1
CDKN1A as a potential target for Eltrombopag treatment in ITP and its regulation of the communication between macrophages and transitional B cells in ITP.CDKN1A作为艾曲泊帕治疗免疫性血小板减少症的潜在靶点及其对免疫性血小板减少症中巨噬细胞与过渡性B细胞之间通讯的调节作用。
Ann Hematol. 2025 Jun 14. doi: 10.1007/s00277-025-06436-5.
2
Expansion of B10 cells : Pathways, techniques and applications in transplantation (Review).B10细胞的扩增:移植中的途径、技术及应用(综述)
Int J Mol Med. 2025 Feb;55(2). doi: 10.3892/ijmm.2024.5470. Epub 2024 Dec 13.
3
High dimensional proteomic mapping of bone marrow immune characteristics in immune thrombocytopenia.免疫性血小板减少症骨髓免疫特征的高维蛋白质组学图谱。
Sci China Life Sci. 2024 Aug;67(8):1635-1647. doi: 10.1007/s11427-023-2520-4. Epub 2024 Apr 19.
4
Diffuse large B‑cell lymphoma and monoclonal gammopathy secondary to immune thrombocytopenic purpura: A case report.弥漫性大B细胞淋巴瘤继发于免疫性血小板减少性紫癜的单克隆丙种球蛋白病:一例报告。
Oncol Lett. 2023 Apr 19;25(6):237. doi: 10.3892/ol.2023.13823. eCollection 2023 Jun.
5
Emerging data on thrombopoietin receptor agonists for management of chemotherapy-induced thrombocytopenia.新兴的促血小板生成素受体激动剂在化疗引起的血小板减少症管理中的应用数据。
Expert Rev Hematol. 2023 May;16(5):365-375. doi: 10.1080/17474086.2023.2201428. Epub 2023 Apr 14.
6
Interactions between Platelets and Tumor Microenvironment Components in Ovarian Cancer and Their Implications for Treatment and Clinical Outcomes.卵巢癌中血小板与肿瘤微环境成分之间的相互作用及其对治疗和临床结果的影响。
Cancers (Basel). 2023 Feb 17;15(4):1282. doi: 10.3390/cancers15041282.
7
How we treat primary immune thrombocytopenia in adults.成人原发免疫性血小板减少症的治疗方法。
J Hematol Oncol. 2023 Jan 19;16(1):4. doi: 10.1186/s13045-023-01401-z.
8
Efficacy and safety of cyclosporine-based regimens for primary immune thrombocytopenia: a systematic review and meta-analysis.环孢素为基础的方案治疗原发免疫性血小板减少症的疗效和安全性:系统评价和荟萃分析。
J Int Med Res. 2023 Jan;51(1):3000605221149870. doi: 10.1177/03000605221149870.
9
Adapted guideline for the diagnosis and treatment of primary immune thrombocytopenia for Chinese children (2021).《中国儿童原发性免疫性血小板减少症诊疗指南(2021年版)》
Pediatr Investig. 2022 Feb 21;6(2):63-74. doi: 10.1002/ped4.12305. eCollection 2022 Jun.
10
Exploring the Potential of Eltrombopag: Room for More?探索艾曲泊帕的潜力:还有更多空间吗?
Front Pharmacol. 2022 May 23;13:906036. doi: 10.3389/fphar.2022.906036. eCollection 2022.

本文引用的文献

1
Immune regulatory function of B cells.B 细胞的免疫调节功能。
Annu Rev Immunol. 2012;30:221-41. doi: 10.1146/annurev-immunol-020711-074934. Epub 2012 Jan 3.
2
Human CD19(+)CD25(high) B regulatory cells suppress proliferation of CD4(+) T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells.人 CD19(+)CD25(high)B 调节性细胞抑制 CD4(+)T 细胞的增殖,并增强 T 调节细胞中 Foxp3 和 CTLA-4 的表达。
Autoimmun Rev. 2012 Jul;11(9):670-7. doi: 10.1016/j.autrev.2011.11.018. Epub 2011 Dec 2.
3
Immunologic effects of rituximab on the human spleen in immune thrombocytopenia.利妥昔单抗对免疫性血小板减少症患者脾脏的免疫作用。
Blood. 2011 Oct 20;118(16):4394-400. doi: 10.1182/blood-2011-03-344051. Epub 2011 Aug 29.
4
Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells.缺乏内源性产生 IL-10 的调节性 B 细胞的小鼠发生更严重的疾病,并表现出 Th1/Th17 的频率增加,但调节性 T 细胞减少。
J Immunol. 2011 May 15;186(10):5569-79. doi: 10.4049/jimmunol.1100284. Epub 2011 Apr 4.
5
High-dose dexamethasone shifts the balance of stimulatory and inhibitory Fcgamma receptors on monocytes in patients with primary immune thrombocytopenia.大剂量地塞米松可改变原发免疫性血小板减少症患者单核细胞上刺激型和抑制型 Fcγ 受体的平衡。
Blood. 2011 Feb 10;117(6):2061-9. doi: 10.1182/blood-2010-07-295477. Epub 2010 Dec 3.
6
Romiplostim or standard of care in patients with immune thrombocytopenia.罗米司亭或标准治疗用于免疫性血小板减少症患者。
N Engl J Med. 2010 Nov 11;363(20):1889-99. doi: 10.1056/NEJMoa1002625.
7
Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells.鉴定人类中一种罕见的具有 IL-10 能力的 B 细胞亚群,该亚群类似于小鼠调节性 B10 细胞。
Blood. 2011 Jan 13;117(2):530-41. doi: 10.1182/blood-2010-07-294249. Epub 2010 Oct 20.
8
IL-10 produced by activated human B cells regulates CD4(+) T-cell activation in vitro.活化的人 B 细胞产生的白细胞介素-10 可调节体外 CD4(+)T 细胞的活化。
Eur J Immunol. 2010 Oct;40(10):2686-91. doi: 10.1002/eji.201040673.
9
Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents.促血小板生成素治疗慢性免疫性血小板减少症患者的调节性 T 细胞活性增强。
Blood. 2010 Nov 25;116(22):4639-45. doi: 10.1182/blood-2010-04-281717. Epub 2010 Aug 5.
10
B cells as therapeutic targets in SLE.B 细胞作为 SLE 的治疗靶点。
Nat Rev Rheumatol. 2010 Jun;6(6):326-37. doi: 10.1038/nrrheum.2010.68.

免疫性血小板减少症患者的调节性 B 细胞缺陷。

Defective regulatory B-cell compartment in patients with immune thrombocytopenia.

机构信息

Laboratory of Complement Biology, New York Blood Center, NY, USA.

出版信息

Blood. 2012 Oct 18;120(16):3318-25. doi: 10.1182/blood-2012-05-432575. Epub 2012 Aug 2.

DOI:10.1182/blood-2012-05-432575
PMID:22859611
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3476542/
Abstract

B lymphocytes producing antiplatelet autoantibodies play a major role in autoimmune thrombocytopenia (ITP). However, certain B cells, including the human CD19(+)CD24(hi)CD38(hi) subpopulation, possess regulatory functions mediated partly by IL-10. In a cohort of chronic ITP patients with low platelet counts who consisted of patients off treatment, we found a lower frequency of CD19(+)CD24(hi)CD38(hi) in the peripheral compartment of nonsplenectomized patients (P = .03). IL-10 expression after activation was decreased in all ITP circulating CD19(+) subpopulations (P < .03), and inhibition of monocyte TNF-α expression by activated B cells was reduced in patients with platelet numbers of < 50 × 10(9) cells/L (P = .001), indicating that regulatory B cells of patients with ITP are functionally impaired in their ability to dampen monocyte activation. Interestingly, in nonsplenectomized patients whose platelet counts were elevated after treatment with thrombopoietic agents, the frequency of CD19(+)CD24(hi)CD38(hi) B cells was increased compared with those before treatment (P = .02). Altogether, these data indicate a compromised regulatory B-cell compartment as an additional defect in immune regulation in patients with chronic ITP that may be restored in responders to thrombopoietic treatment.

摘要

产生抗血小板自身抗体的 B 淋巴细胞在自身免疫性血小板减少症 (ITP) 中起主要作用。然而,某些 B 细胞,包括人类 CD19(+)CD24(hi)CD38(hi)亚群,具有部分由 IL-10 介导的调节功能。在一组血小板计数较低的慢性 ITP 患者队列中,我们发现未接受治疗的非脾切除术患者外周血中 CD19(+)CD24(hi)CD38(hi)的频率较低(P =.03)。所有 ITP 循环 CD19(+)亚群的激活后 IL-10 表达均降低(P <.03),并且在血小板计数 < 50 × 10(9)个/细胞/L 的患者中,激活的 B 细胞对单核细胞 TNF-α表达的抑制作用降低(P =.001),表明 ITP 患者的调节性 B 细胞在抑制单核细胞激活的能力方面存在功能障碍。有趣的是,在接受促血小板生成剂治疗后血小板计数升高的非脾切除术患者中,与治疗前相比,CD19(+)CD24(hi)CD38(hi)B 细胞的频率增加(P =.02)。总的来说,这些数据表明调节性 B 细胞区室受损是慢性 ITP 患者免疫调节的另一个缺陷,在对促血小板生成治疗有反应的患者中可能会得到恢复。